ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

MIRO MiroMatrix Medical Inc

3.39
0.00 (0.00%)
After Hours
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
MiroMatrix Medical Inc NASDAQ:MIRO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.39 3.50 3.67 0 00:00:00

Miromatrix CEO Jeff Ross to Present at the 2023 Cell & Gene Meeting on the Mesa

05/10/2023 9:30pm

GlobeNewswire Inc.


MiroMatrix Medical (NASDAQ:MIRO)
Historical Stock Chart


From Nov 2022 to Nov 2024

Click Here for more MiroMatrix Medical Charts.

Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that CEO Jeff Ross will present at the 2023 Cell & Gene Meeting on the Mesa in Carlsbad, CA. The three-day event, held this year on October 10-12, will feature presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies.

Mr. Ross will deliver his remarks at 5:30 pm PT on Wednesday, October 11th in the Ecolab Lifesciences Ballroom. Registration for either in-person attendance or virtual participation is available here.

About MiromatrixMiromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.

Investor Contact
Greg Chodaczek
347-620-7010
ir@miromatrix.com

Media Contact:
Christina Campbell
612-924-3793
Christina@media-minefield.com

1 Year MiroMatrix Medical Chart

1 Year MiroMatrix Medical Chart

1 Month MiroMatrix Medical Chart

1 Month MiroMatrix Medical Chart

Your Recent History

Delayed Upgrade Clock